Related references
Note: Only part of the references are listed.Plasma Cell-Free DNA in Ovarian Cancer An Independent Prognostic Biomarker
Aparna A. Kamat et al.
CANCER (2010)
Ovarian cancer: the duplicity of CA125 measurement
Amer K. Karam et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Combined use of biomarkers for detection of ovarian cancer in high-risk women
Martin Donach et al.
TUMOR BIOLOGY (2010)
Role of breast regression protein-39/YKL-40 in asthma and allergic responses
Chun Geun Lee et al.
ALLERGY ASTHMA & IMMUNOLOGY RESEARCH (2010)
Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer
Digant Gupta et al.
JOURNAL OF OVARIAN RESEARCH (2010)
YKL-40 tissue expression and plasma levels in patients with ovarian cancer
Estrid V. S. Hogdall et al.
BMC CANCER (2009)
YKL-40-an emerging biomarker in cardiovascular disease and diabetes
Camilla N. Rathcke et al.
CARDIOVASCULAR DIABETOLOGY (2009)
Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors
Corina Kohler et al.
MOLECULAR CANCER (2009)
YKL-40, a secreted glycoprotein, promotes tumor angiogenesis
R. Shao et al.
ONCOGENE (2009)
Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer
A. Prat et al.
ANNALS OF ONCOLOGY (2008)
Mitochondrial DNA in serum of patients with prostate cancer:: a predictor of biochemical recurrence after prostatectomy
Joerg Ellinger et al.
BJU INTERNATIONAL (2008)
Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors
Rebecca R. Zachariah et al.
OBSTETRICS AND GYNECOLOGY (2008)
Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance
Emmanuelle Gormally et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2007)
Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer
Niven Mehra et al.
CLINICAL CANCER RESEARCH (2007)
Early detection of ovarian cancer
Donna Badgwell et al.
DISEASE MARKERS (2007)
Circulating cell-free DNA - A novel biomarker for response to therapy in ovarian carcinoma
Aparna A. Kamat et al.
CANCER BIOLOGY & THERAPY (2006)
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer
M Markmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Serum YKL-40, a new prognostic biomarker in cancer patients?
JS Johansen et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?
SM Crawford et al.
ANNALS OF ONCOLOGY (2005)
Early detection and prognosis of ovarian cancer using serum YKL-40
J Dupont et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer
H Dehn et al.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA (2003)
Mitochondrial DNA alterations in cancer
WC Copeland et al.
CANCER INVESTIGATION (2002)
Molecular cloning of the CA125 ovarian cancer antigen - Identification as a new mucin, MUC16
BWT Yin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
MK Tuxen et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
